Isoflavone Plus
Natural health product licensed in Canada
- Licence holder
- Nature's Ace Biopharmaceutical Inc.
- NPN or DIN-HM
- 80080862
- Status
- Active licence
- Licence date
- 24 October 2017
- Revision date
- Not provided
- Form
- Capsule, molle
- Route of administration
- Orale
- Application type
- Non traditionnelle
If this product were sold in France
No point flagged by the rules we apply.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| 4',5,7-Trihydroxyisoflavone Source : Glycine max - Graine | 17 EAI | Not calculated |
| Oenothera biennis Source : Graine(s) Potency : 365 mg Linoleic acid | 500 mg | Not calculated |
| Oenothera biennis Source : Graine(s) Potency : 45 mg gamma-Linolenic acid | Not specified | Not calculated |
| 4',5,7-Trihydroxyisoflavone Source : Glycine max - Graine | 50 mg | Not calculated |
Non-medicinal ingredients
Dioxyde de titane, Lécithine, Gélatine, Glycérine, Cire d'abeille, Caramel
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Femmes ménopausées et en postménopause | Not specified | 1 Capsule | 2 Tous les jours |
Uses authorised in Canada
Isoflavone Plu may help reduce menopausal symptoms (such as hot flashes and/or night sweats).
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
- Précautions et mises en garde
Ensure you are up-to-date on mammograms and gynaecological evaluations prior to use. Consult a health care practitioner if symptoms worsen. Consult a health care practitioner prior to use if you are taking blood thinners and/or hormone replacement therapy, including thyroid hormone replacement therapy. Consult a health care practitioner prior to use if you have a history of hormonal or gynaecological disease, including ovarian cancer, endometriosis, and/or uterine fibroids. Consult a health care practitioner prior to use if you have a liver disorder or develop liver related symptoms (e.g. abdominal pain, jaundice, dark urine). Discontinue use and consult a health care practitioner if you experience breast pain, discomfort and/or tenderness, or if you experience a recurrence of menstruation and/or uterine spotting. Do not use if you have hypertension.
- Contre-indications
Do not use if you currently or previously have breast cancer and/or breast tumorous or if you have a predisposition to breast cancer, as indicated by an abnormal Mammogram and/or biopsy, or a family member with breast cancer.
Source
Official Health Canada record, licence 80080862
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.